Pacific Edge Placement Increased to NZ $25.4 Million

Pacific Edge Limited (Pacific Edge or the Company) (NZX/ASX: PEB) today announces it has successfully raised NZ$25.4 million of new equity in a placement of new ordinary shares (Placement), after the Directors resolved to increase the Placement and accept oversubscriptions following strong investor demand.

The Placement, which was well supported by existing institutional and other investors, was completed on Tuesday, 12 May 2026. It was priced at NZ$0.17 per share, a 2.3% discount to the closing share price on 8 May 2026, prior to the announcement of the company’s planned equity issue.

As previously announced, Pacific Edge intends to conduct a retail offer to eligible existing shareholders to raise up to NZ$6 million at the same offer price of NZ$0.17 per share (with the ability to accept oversubscriptions at Pacific Edge’s discretion) (Retail Offer). Full details of the Retail Offer will be set out in the Retail Offer Document, which will be released to the NZX and ASX, and sent to eligible shareholders on Thursday, 14 May 2026.

The Placement and Retail Offer are aimed at ensuring Pacific Edge has additional resources and capacity to support ongoing operations and growth, support the company to achieve Medicare re-coverage, and continue evidence generation, product development and innovation.

Chairman, Simon Flood said: “We are delighted with the investor support we have received. The new capital will allow us to consolidate our market position in bladder cancer diagnostics. It will support the Company and its operations to regain Medicare coverage and assist our move towards the broader adoption of our tests by commercial payers in the US and further afield. We are determined not to lose that momentum.”

Pacific Edge Chief Executive, Dr Peter Meintjes, said: “The robust evidence emerging from our clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests with opportunities in the US and in the Asia Pacific Region. We are delighted with the strong support we have received from investors in the Placement to continue to pursue our plans, and we are looking forward to making the Retail Offer to eligible shareholders at the same offer price.”

Pacific Edge is advised on the equity raise by Cameron Partners (investment banking advisers), Harmos Horton Lusk (legal advisers) and The Project (investor relations and communications advisers).

For further information on the detail and timetable of the equity raising please refer to the announcement and presentation dated Friday, 8 May 2026 and released by NZX and ASX on Monday, 11 May 2026.